CLBIO — Corline Biomedical AB Balance Sheet
0.000.00%
- SEK199.86m
- SEK182.20m
- SEK9.78m
Annual balance sheet for Corline Biomedical AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | SAS | SAS | SAS | SAS | — |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 8.9 | 41.6 | 26.2 | 17 | 17.7 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1.67 | 2.77 | 8.47 | 5.22 | 2.63 |
Prepaid Expenses | |||||
Total Current Assets | 11 | 44.8 | 36 | 23.8 | 21 |
Net Property, Plant And Equipment | 0.073 | 0.182 | 0.28 | 0.314 | 0.219 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Total Assets | 58.5 | 102 | 102 | 100 | 94.8 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 6.24 | 9.43 | 7.19 | 6.79 | 7.85 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 6.24 | 9.43 | 7.19 | 6.79 | 7.85 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 52.2 | 92.2 | 94.6 | 93.3 | 86.9 |
Total Liabilities & Shareholders' Equity | 58.5 | 102 | 102 | 100 | 94.8 |
Total Common Shares Outstanding |